Peptide Reference
Retatrutide
Retatrutide
A triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly as the next-generation obesity medication.
Status
clinical
Category
weight loss
Typical cost
Not yet priced (expected $1000-1500/month)
Mechanism
Activates GLP-1 receptors (appetite suppression), GIP receptors (enhanced insulin secretion), and glucagon receptors (increased energy expenditure). The first triple agonist for weight management.
Potential benefits
- Superior weight loss (24%+ in trials)
- Improved glycemic control
- Increased energy expenditure
- Better lipid profiles
- Cardiovascular benefits
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
- Gallbladder issues
Common dosing references
subcutaneous
1-12mg · Weekly
Ongoing
Research notes
Retatrutide phase II trial
2023
Average 24.2% weight loss at 48 weeks with 12mg dose, highest ever reported for obesity drug
Regulatory and sourcing notes
Phase III clinical trials. Not yet FDA-approved. Fast-track designation granted.
Not yet available. Expected FDA submission 2024-2025. Will likely be brand-only initially.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides